PURPOSE: To assess whether, in addition to sparing the parotid glands (PGs), xerostomia after chemotherapy plus intensity-modulated radiotherapy (chemo-IMRT) for head-and-neck cancer is affected by reducing the dose to the other salivary glands. PATIENTS AND METHODS: In a prospective study, 78 patients with Stage III-IV oropharynx/nasopharynx cancer underwent chemo-IMRT, with the aim of sparing the parts of the bilateral PGs, oral cavity (OC) containing the minor salivary glands, and contralateral submandibular gland (SMG) outside the target (when contralateral level I was not a target). Before therapy and periodically for 24 months, validated patient-reported xerostomia questionnaire (XQ) scores and observer-graded xerostomia scores were recorded. Also, the stimulated and unstimulated saliva was measured selectively from each of the PGs and SMGs. The mean OC doses served as surrogates of minor salivary gland dysfunction. Regression models assessed the XQ and observer-graded xerostomia predictors. RESULTS: Statistically significant predictors of the XQ score on univariate analysis included the OC, PG, and SMG mean doses and the baseline XQ score, time since RT, and both stimulated and unstimulated PG saliva flow rates. Similar factors were statistically significant predictors of observer-graded xerostomia. The OC, PG, and SMG mean doses were moderately intercorrelated (r = 0.47-0.55). On multivariate analyses, after adjusting for the PG and SMG doses, the OC mean dose (p < .0001), interval from RT (p < .0001), and stimulated PG saliva (p < .0025) were significant predictors of the XQ scores and the OC mean dose and time for observer-graded xerostomia. Although scatter plots showed no thresholds, an OC mean dose of <40 Gy and contralateral SMG mean dose of <50 Gy were each associated with low patient-reported and observer-rated xerostomia at almost all post-therapy points. CONCLUSION: The PG, SMG, and OC mean doses were significant predictors of both patient-reported and observer-rated xerostomia after chemo-IMRT, with OC doses remaining significant after adjusting for the PG and SMG doses. These results support efforts to spare all the salivary glands by IMRT, beyond the PGs alone.
PURPOSE: To assess whether, in addition to sparing the parotid glands (PGs), xerostomia after chemotherapy plus intensity-modulated radiotherapy (chemo-IMRT) for head-and-neck cancer is affected by reducing the dose to the other salivary glands. PATIENTS AND METHODS: In a prospective study, 78 patients with Stage III-IV oropharynx/nasopharynx cancer underwent chemo-IMRT, with the aim of sparing the parts of the bilateral PGs, oral cavity (OC) containing the minor salivary glands, and contralateral submandibular gland (SMG) outside the target (when contralateral level I was not a target). Before therapy and periodically for 24 months, validated patient-reported xerostomia questionnaire (XQ) scores and observer-graded xerostomia scores were recorded. Also, the stimulated and unstimulated saliva was measured selectively from each of the PGs and SMGs. The mean OC doses served as surrogates of minor salivary gland dysfunction. Regression models assessed the XQ and observer-graded xerostomia predictors. RESULTS: Statistically significant predictors of the XQ score on univariate analysis included the OC, PG, and SMG mean doses and the baseline XQ score, time since RT, and both stimulated and unstimulated PG saliva flow rates. Similar factors were statistically significant predictors of observer-graded xerostomia. The OC, PG, and SMG mean doses were moderately intercorrelated (r = 0.47-0.55). On multivariate analyses, after adjusting for the PG and SMG doses, the OC mean dose (p < .0001), interval from RT (p < .0001), and stimulated PG saliva (p < .0025) were significant predictors of the XQ scores and the OC mean dose and time for observer-graded xerostomia. Although scatter plots showed no thresholds, an OC mean dose of <40 Gy and contralateral SMG mean dose of <50 Gy were each associated with low patient-reported and observer-rated xerostomia at almost all post-therapy points. CONCLUSION: The PG, SMG, and OC mean doses were significant predictors of both patient-reported and observer-rated xerostomia after chemo-IMRT, with OC doses remaining significant after adjusting for the PG and SMG doses. These results support efforts to spare all the salivary glands by IMRT, beyond the PGs alone.
Authors: Anke Petra Jellema; Patricia Doornaert; Ben J Slotman; C Rene Leemans; Johannes A Langendijk Journal: Radiother Oncol Date: 2005-10-26 Impact factor: 6.280
Authors: Edmond H N Pow; Dora L W Kwong; Anne S McMillan; May C M Wong; Jonathan S T Sham; Lucullus H T Leung; W Keung Leung Journal: Int J Radiat Oncol Biol Phys Date: 2006-11-15 Impact factor: 7.038
Authors: Kauko Saarilahti; Mauri Kouri; Juhani Collan; Aki Kangasmäki; Timo Atula; Heikki Joensuu; Mikko Tenhunen Journal: Radiother Oncol Date: 2006-03-27 Impact factor: 6.280
Authors: Michael K M Kam; Sing-Fai Leung; Benny Zee; Ricky M C Chau; Joyce J S Suen; Frankie Mo; Maria Lai; Rosalie Ho; Kin-yin Cheung; Brian K H Yu; Samuel K W Chiu; Peter H K Choi; Peter M L Teo; Wing-hong Kwan; Anthony T C Chan Journal: J Clin Oncol Date: 2007-11-01 Impact factor: 44.544
Authors: Jeffrey M Vainshtein; Dominic H Moon; Felix Y Feng; Douglas B Chepeha; Avraham Eisbruch; Matthew H Stenmark Journal: Int J Radiat Oncol Biol Phys Date: 2015-04-01 Impact factor: 7.038
Authors: Primož Strojan; Katherine A Hutcheson; Avraham Eisbruch; Jonathan J Beitler; Johannes A Langendijk; Anne W M Lee; June Corry; William M Mendenhall; Robert Smee; Alessandra Rinaldo; Alfio Ferlito Journal: Cancer Treat Rev Date: 2017-07-18 Impact factor: 12.111
Authors: Ken Randall; Jason Stevens; Juan Fernando Yepes; Marcus E Randall; Mahesh Kudrimoti; Jonathan Feddock; Jing Xi; Richard J Kryscio; Craig S Miller Journal: Oral Surg Oral Med Oral Pathol Oral Radiol Date: 2013-03-22
Authors: Klaudia U Hunter; Matthew Schipper; Felix Y Feng; Teresa Lyden; Mark Haxer; Carol-Anne Murdoch-Kinch; Benjamin Cornwall; Connie S Y Lee; Douglas B Chepeha; Avraham Eisbruch Journal: Int J Radiat Oncol Biol Phys Date: 2012-10-03 Impact factor: 7.038